Increasing Access to FDA Inspection Reports on Irregularities and Misconduct in Clinical Trials

Abstract

This Viewpoint reviews notable examples of clinical trial misconduct identified by routine US Food and Drug Administration (FDA) clinical trial site inspections and argues that making inspection reports publicly available on the agency's and trial registry websites is important to maintaining the integrity of clinical research.